Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-01-21 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting of shareholders (临时股东大会) for Harbin Gloria Pharmaceuticals Co., Ltd. It includes details about the meeting time, location, voting procedures, agenda items, and proxy forms. There is no financial data, earnings, or management discussion. It is an announcement informing shareholders about the meeting and how to participate, including voting instructions and proxy forms. The document length is 4031 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2025-01-21 Chinese
第六届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 19th meeting of the 6th Board of Directors of Harbin Yuheng Pharmaceutical Co., Ltd. It details decisions such as the repurchase and cancellation of restricted shares from former employees and the proposal to convene an extraordinary general meeting. The document includes voting results and references to further announcements on designated media. It does not contain financial statements, audit information, or detailed financial data. It is not a full report but an official announcement of board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1095 characters), and it is not merely announcing a report publication but providing substantive board decisions.
2025-01-21 Chinese
第六届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. It details the election of a new supervisory board chairman and approval of a stock repurchase and cancellation plan related to restricted shares of former employees. The document includes voting results and a biography of the newly elected chairman. It is a formal announcement of board/management decisions rather than a full report or financial statement. The content fits the category of Board/Management Information (MANG) as it announces changes in the company's supervisory board and related governance actions. The document length is short and does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. It is not a regulatory filing or report publication announcement since it contains substantive decisions and voting results from the supervisory board meeting.
2025-01-21 Chinese
2024年限制性股票激励计划之回购注销部分限制性股票事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted stock under a 2024 restricted stock incentive plan by Harbin Yuheng Pharmaceutical Co., Ltd. It details the legal review and compliance with relevant laws and regulations concerning the stock repurchase and cancellation. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a capital/financing activity (stock repurchase and cancellation). It is not an announcement of a report publication or a certification. The content focuses on the legality and authorization of the stock repurchase and cancellation, which is a capital structure change. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4006 characters, which is relatively short but contains substantive legal opinion on a financing-related matter, not just an announcement or notice.
2025-01-21 Chinese
关于回购并注销离职人员已获授但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares granted to employees who have left the company. It details the board and supervisory meetings approving the repurchase, the reasons for repurchase, the number of shares, repurchase price, funding source, and the impact on share capital structure. The document is a formal disclosure about a share repurchase and cancellation event related to restricted stock incentives. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, presentation, or legal proceeding update. The content fits the category of a Transaction in Own Shares (POS), as it reports the company's buyback and cancellation of its own shares under a stock incentive plan.
2025-01-21 Chinese
2024年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2024 年度业绩预告' which translates to '2024 Annual Performance Forecast'. It provides estimated net profit figures for the fiscal year 2024 and compares them to the previous year. It explicitly states that the forecast is preliminary and unaudited, and that actual financial data will be in the 2024 annual report. The document length is short (1150 characters), and it is an announcement of expected financial results rather than a full financial report. There is no detailed financial statement or comprehensive analysis, only a forecast and risk warning. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results or forecasts. FY 2024
2025-01-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.